Menu
Recruiting NCT07311941

Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event

— Observational Hyperlipidemia Cardio Vascular Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Hyperlipidemia, Cardio Vascular Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Hong Kong
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study

Overview

Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD). Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain. This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.

Primary outcome measures

  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Baseline]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: week 8]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Week 26]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Week 52]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Baseline]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Week 8]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Week 26]
  • Low-density lipoprotein cholesterol (LDL-C) level [Time frame: Week 52]
Secondary outcome measures (12)
  • Rate of subject meeting LDL-C target [Time frame: Week 26]
  • Rate of subject meeting LDL-C target [Time frame: Week 26]
  • Rate of subject meeting LDL-C target [Time frame: Week 26]
  • 12-Item Short Form Survey (SF-12) [Time frame: Baseline]
  • 12-Item Short Form Survey (SF-12) [Time frame: Week 8]
  • 12-Item Short Form Survey (SF-12) [Time frame: Week 26]
  • 12-Item Short Form Survey (SF-12) [Time frame: Week 52]
  • Rate of major adverse cardiovascular event (MACE) [Time frame: Baseline]
  • Rate of major adverse cardiovascular event (MACE) [Time frame: Week 8]
  • Rate of major adverse cardiovascular event (MACE) [Time frame: Week 26]
  • Rate of major adverse cardiovascular event (MACE) [Time frame: Week52]
  • Modification of lipid lowering therapy (LLT) [Time frame: Week 8]

Eligibility criteria

Inclusion criteria

  • Age >18
  • (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
  • (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease

Exclusion criteria

  • Inability to provide valid consent by the patient or his legal guardian
  • Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
  • Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Hong Kong · 1 center
  • Prince of Wales Hospital — Shatin

Identifiers

NCT: NCT07311941 · 2024.356

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗